Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension of HZN-825 in diffuse cutaneous systemic sclerosis
2021-006271-42Phase 2Active
- Sponsor
- Horizon Therapeutics
- Start
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of fipaxalparant in diffuse cutaneous systemic sclerosis (dcSSc) and systemic sclerosis (SSc), sponsored by Horizon Therapeutics. Primary endpoint: Change from both baselines in FVC % predicted at Week 52. Started Oct 2022; status: active.
02
Drugs
fipaxalparant
03
Conditions
diffuse cutaneous systemic sclerosis (dcSSc)systemic sclerosis (SSc)
Beyond the preview
Go deeper on 2021-006271-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-006271-42.